Psoriasis Biologics and Heart Disease Risk Everyday Health MenuNewslettersSearch Psoriasis News
Psoriasis Biologics May Reduce Heart Disease Risk Study Suggests
New research has found that drugs like adalimumab and ustekinumab might lower levels of a dangerous type of coronary plaque. By Brian P. DunleavySeptember 22, 2020Everyday Health ArchiveFact-CheckedThe research on psoriasis biologics and heart-disease risk is early-stage but exciting.Everyday HealthPeople with psoriasis who are on biologic therapies may get an added boost to their overall health: a reduced risk of heart disease. According to a study published in the September 2020 issue of the journal Circulation: Cardiovascular Imaging, people who received biologics like adalimumab and ustekinumab for one year to manage their psoriasis had lower levels of a type of coronary plaque called lipid-rich necrotic core (LRNC) compared with people who didn’t receive the drugs. LRNC has been linked with higher risk of heart attack and stroke in people with coronary artery disease. The Centers for Disease Control and Prevention (CDC) describes plaque as cholesterol deposits that accumulate on the walls of arteries, causing blockages that can lead to coronary artery disease. Coronary artery disease is the most common form of heart disease in the United States, affecting an estimated 18 million people, the CDC says. “[Our] current hypothesis is that treatment of psoriasis may result in a lowering of the risk of cardiovascular disease over time,” explains Joel M. Gelfand, MD, director of the Psoriasis and Phototherapy Treatment Center at University of Pennsylvania’s Perelman School of Medicine Philadelphia, who was one of the coauthors of the new study. RELATED: The Consumer s Guide to Biologics for Psoriasis How Biologics Work
It seems biologic therapy as well as phototherapy — two commonly used treatments for psoriasis — may both work to reduce levels of LRNC in the blood. LRNC is among several leading biomarkers (measurable signs) that can predict future heart attacks, Dr. Gelfand says. Biologics, which target specific areas of the immune system, have been used for psoriasis treatment since the early 2000s. The biologics used to treat psoriatic disease block the action of a specific type of immune cell — a T cell — or proteins in the immune system, such as tumor necrosis factor-alpha (TNF-alpha), interleukin 17-A, or interleukins 12 and 23, according to the National Psoriasis Foundation. TNF-alpha and the interleukins all play a major role in psoriasis and psoriatic arthritis. RELATED: 7 Signs You May Need to Change Your Psoriasis Treatment Related
Everything You Need to Know About Biologics for Psoriasis
Get the facts about the most targeted psoriasis treatment option.…Learn More A Closer Look at the Study
For the new study, Gelfand and his colleagues enrolled 209 people with psoriasis who had not yet been treated with biologics. Roughly one-half were prescribed biologic therapies to treat their condition, while the rest were not. LRNC for people in both groups was assessed using coronary computed tomography angiography, with measurements taken at the beginning of the study and, again, one year later. On average, those who received biologic therapy saw their LRNC decline from 3.12 square millimeters (mm2) to 2.97 mm2 — or about 5 percent. Conversely, those who weren’t on biologic therapy saw LRNC increase from 3.12 to 3.34 mm2, on average — a 6 percent rise. RELATED: 8 Health Conditions Linked to Psoriasis Heart Disease and Psoriasis
Although larger studies are needed to confirm the positive effects of biologics on LRNC and heart disease risk, the findings are “exciting,” Gelfand says, because recent research suggests that people with psoriasis are at increased risk for heart disease. “And this risk is more clinically significant in those with more severe skin disease,” Gelfand notes. “People with psoriasis should be screened for traditional cardiovascular risk factors such as high blood pressure, diabetes, and high cholesterol, and they should adopt a heart-healthy lifestyle — whether they’re on biologics or not.” RELATED: Psoriasis and Heart Disease: The Hidden Connection NEWSLETTERS Sign up for our Psoriasis Newsletter
SubscribeBy subscribing you agree to the Terms of Use and Privacy Policy. The Latest in Psoriasis
What s a Typical Day Like With Psoriasis
By Howard ChangSeptember 30, 2022 Best and Worst Drinks for Psoriasis
Can drinking more water help ease psoriasis symptoms? How good or bad is alcohol, tea, or soda? Here’s how to make the healthiest choices for your skin...By Becky UphamSeptember 30, 2022 FDA Approves Sotyktu Deucravacitinib for Moderate-to-Severe Psoriasis
This daily pill could be an option for patients who want to avoid injectable medications.By Becky UphamSeptember 12, 2022 My 5 Biggest Psoriasis Mistakes
By Howard ChangSeptember 2, 2022 My 4-Part Action Plan for Building Confidence
By Howard ChangAugust 15, 2022 FDA Approves New Treatment for People With Plaque Psoriasis
Zoryve is the first steroid-free topical cream to specifically demonstrate efficacy for psoriasis found in skin folds.By Becky UphamAugust 1, 2022 6 Ways Psoriasis Is Different for Women
From emotional health to the impact of sex hormones, women with psoriasis have special concerns.By Pamela AppeaJuly 26, 2022 How to Safely Remove Psoriasis Scales
Removing psoriasis scales can have benefits, but don’t pick or peel them, which can trigger flares. There are several safe and effective ways to free ...By Elizabeth YunJuly 26, 2022 What to Know About CBD for Treating Plaque Psoriasis
This component of cannabis doesn’t bring on a “high” — but it may help fight inflammation and ease anxiety and stress that trigger flares.By Johanna NeesonJuly 26, 2022 Psoriasis Has Changed How I Eat
By Howard ChangJuly 7, 2022 MORE IN Is Psoriasis Contagious
7 Health Conditions Linked to Psoriasis
The Consumer s Guide to Biologics for Psoriasis